Petrylak D.P.de Wit R.Chi K.N.Drakaki A.Sternberg C.N.Nishiyama H.Castellano D.Hussain S.Fléchon, AudeAudeFléchonBamias A.Yu E.Y.Lee Y.-G.Cort?s L.V.Flores C.L.U.Blaisse R.J.B.Erdkamp F.L.G.Aarts M.J.B.Wojcik-Tomaszewska J.Tomczak P.Sikora-Kupis B.Schenker M.van der Heijden M.S.Herzal A.A.Udrea A.A.Karlov P.Fomkin R.Pulido E.G.Mignorance J.I.D.Gauna D.C.Rodr?guez-Vida A.Su Y.-L.Lin C.-L.Matsubara N.CHIA-CHI LINYeh S.-P.?i?in I.Erman M.Urun Y.Golovko Y.Bondarenko I.Sinielnikov I.Crabb S.Syndikus I.Alekseev B.Huddart R.Sundar S.Chowdhury S.Sarwar N.Flaig T.Pan C.X.Schwarz J.Cultrera J.Hainsworth J.Herms B.Necchi A.Lawler W.Lowe T.Tagawa S.Aragon-Ching J.Vaishampayan U.G?czi L.Ou Y.-C.Coskun H.S.Su W.-P.Hegemann M.Percent I.J.Lee J.-L.Tucci M.Semenov A.Laestadius F.Peer A.Tortora G.Safina S.del Muro X.G.Rodriguez-Vida A.Cicin I.Harputluoglu H.Widau R.C.Liepa A.M.Walgren R.A.Hamid O.Zimmermann A.H.Bell-McGuinn K.M.Powles T.Wong S.-L.S.Tan T.H.Hovey E.J.Clay T.D.Ng S.S.W.Rutten A.Machiels J.-P.Dumez H.Cheng S.Y.-S.Ferrario C.Sengeloev L.Jensen N.V.Thibault C.Laguerre B.Joly F.Flechon A.Culine S.Becht C.Niegisch G.St?ckle M.Grimm M.-O.Gakis G.Schultze-Seemann W.Kalofonos H.Mavroudis D.Papandreou C.Karavasilis V.R?v?sz J.Geczi L.Rosenbaum E.Leibowitz-Amit R.Kejzman D.Sarid D.Scagliotti G.V.Bracarda S.Massari F.Osawa T.Miyajima N.Shinohara N.Fukuta F.Ohyama C.Obara W.Yamashita S.Tomita Y.Kawai K.Fukasawa S.Oyama M.Yonese J.Nagata M.Uemura M.Nishimura K.Kawakita M.Tsunemori H.Hashine K.Inokuchi J.Yokomizo A.Nagamori S.Lee H.J.Park S.H.Rha S.Y.Kim Y.J.2022-09-152022-09-1520170140-6736https://www.scopus.com/inward/record.uri?eid=2-s2.0-85029228806&doi=10.1016%2fS0140-6736%2817%2932365-6&partnerID=40&md5=00130ac639afc2fca4e05668a4242762https://scholars.lib.ntu.edu.tw/handle/123456789/620276[SDGs]SDG3Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trialjournal article10.1016/S0140-6736(17)32365-6289163712-s2.0-85029228806